# Elias Jabbour

Source: https://onco.cc/people/elias-jabbour/  
OnCo record `elias-jabbour` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL.

## Summary

Elias Jabbour led the MD Anderson regimens combining low-intensity chemotherapy with inotuzumab ozogamicin and blinatumomab in older adults with ALL, and the chemotherapy-free ponatinib plus blinatumomab regimen for Philadelphia-positive ALL, which produce complete molecular remissions in most patients and challenge the need for transplant. He was senior author of INO-VATE and leads adult ALL research at MD Anderson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: all; immunotherapy; chemo-free
- Role: Professor of Leukemia, MD Anderson Cancer Center
- Specialisms: Adult acute lymphoblastic leukaemia; Antibody and bispecific therapy; Chemotherapy-free regimens; Philadelphia-positive ALL

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Jabbour%20E%5BAuthor%5D%20acute%20lymphoblastic%20leukemia%20blinatumomab

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [INO-VATE ALL](https://onco.cc/trials/ino-vate/)
- key papers: [INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL](https://onco.cc/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/)

---
JSON: https://onco.cc/api/v1/entities/elias-jabbour.json